Tumor cell-targeted PDT extensively sensitized CRC cells to the tumor-homing TRAIL variant by increasing death receptor expression, which resulted in the eradication of tumor xenografts of CRC cells with both chemotherapeutic MDR and TRAIL resistance. The gene discussed is TNFSF10; the disease is colorectal carcinoma.